Patient demographics at the time of TKI cessation
| Characteristics . | MolR (n = 22) . | TFR (n = 22) . |
|---|---|---|
| Drug at time of cessation, n (%) | ||
| Imatinib | 11 (50) | 11 (50) |
| Nilotinib | 3 (13.6) | 7 (31.8) |
| Dasatinib | 8 (36.4) | 4 (18.2) |
| Age at TKI discontinuation, median (range), y | 61 (35-81) | 60 (34-78) |
| Gender, female/male | 13/9 | 13/9 |
| Median duration (range) of TKI therapy before cessation, y | 5.4 (3.2-16.7) | 5.0 (3.0-16.6) |
| Median duration (range) of MR 4.0, y | 3.4 (2.0-13.2) | 4.2 (2.6-12.8) |
| Time to relapse, median (range), mo | 5.3 (2.3-33.6) | - |
| Duration of follow-up (in TFR), median (range), mo | - | 26.6 (12.0-188.0) |
| Characteristics . | MolR (n = 22) . | TFR (n = 22) . |
|---|---|---|
| Drug at time of cessation, n (%) | ||
| Imatinib | 11 (50) | 11 (50) |
| Nilotinib | 3 (13.6) | 7 (31.8) |
| Dasatinib | 8 (36.4) | 4 (18.2) |
| Age at TKI discontinuation, median (range), y | 61 (35-81) | 60 (34-78) |
| Gender, female/male | 13/9 | 13/9 |
| Median duration (range) of TKI therapy before cessation, y | 5.4 (3.2-16.7) | 5.0 (3.0-16.6) |
| Median duration (range) of MR 4.0, y | 3.4 (2.0-13.2) | 4.2 (2.6-12.8) |
| Time to relapse, median (range), mo | 5.3 (2.3-33.6) | - |
| Duration of follow-up (in TFR), median (range), mo | - | 26.6 (12.0-188.0) |
There was no significant difference in age, duration of TKI therapy, or median duration of MR 4.0 (BCR::ABL1 IS ≤ 0.01%) between the MolR and TFR groups.